Full text not available from this repository.

Abstract

What is known and objective: It is 20 years since the US Food and Drug Administrationapproved the first successful monoclonal anticancer antibody, trastuzumab. Thetherapeutic utility of monoclonal antibodies in cancer is often limited by partial clinicalresponses and the development of tumour resistance. An expanding strategy, tobe reviewed here, to overcome the limited response and resistance to monotherapyutilizes concurrent treatment with two synergistic monoclonal antibodies.Comment: Key examples include two monoclonal antibodies, each engaging a distinctsite of human epidermal growth factor receptor 2 (HER2), in the treatment ofbreast cancer and a combination of antibodies to two distinct T-cell antigens for thetreatment of melanoma. Here, we provide an overview of the rationale and evidencefor using selected monoclonal antibodies in combination for treating some cancers,along with potential hazards, especially autoimmune-related toxicities.What is new and conclusion: Thorough research, the development of panels of biomarkersand individualization of therapy will be necessary to optimize the use ofthese combinations and minimize the substantial risk of overstimulating the immunesystem.

Item Type:	Article
Authors/Creators:	Peterson, GM and Thomas, J and Yee, KC and Kosari, S and Naunton, M and Olesen, IH
Keywords:	cancer, combination, immune checkpoint, monoclonal antibody, toxicity
Journal or Publication Title:	Journal of Clinical Pharmacy and Therapeutics
Publisher:	Blackwell Publishing Ltd
ISSN:	0269-4727
DOI / ID Number:	https://doi.org/10.1111/jcpt.12750
Copyright Information:	© 2018 John Wiley & Sons Ltd
Related URLs:	UTAS Profile: Peterson, GM
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page